Navamedic ASA (OSL:NAVA)

Market Cap	388.58M
Revenue (ttm)	523.56M
Net Income (ttm)	-32.38M
Shares Out	17.66M
EPS (ttm)	-1.85
PE Ratio	n/a
Forward PE	22.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,802
Average Volume	9,036
Open	21.60
Previous Close	21.50
Day's Range	21.60 - 21.90
52-Week Range	17.10 - 32.00
Beta	0.33
RSI	38.01
Earnings Date	Oct 28, 2025

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Losses were -5.49 million, -59.92% less than in 2023.